TABLE 1.
Characteristics of participants at baseline
| Code | Age (year) | Sex | Etiology | LC | Body weight (kg) | TNM staging a | Previous sorafenib treatment | Previous HCC treatment |
|---|---|---|---|---|---|---|---|---|
| C001 | 61 | F | HBV | No | 62.5 | IVA | No | OP, TACE |
| C002 | 66 | M | unknown | No | 78 | IVB | 30 days (TP) | OP, TACE |
| C003 | 65 | M | HBV | No | 50.2 | IVB | 7 days (ISE) | OP |
| C004 | 53 | M | HBV | No | 45 | IVB | 7 days (ISE) | TACE |
| C005 | 59 | M | HBV | No | 63.1 | IIIB | 60 days (TP) | RT, TACE |
| C006 | 43 | M | HBV | Yes | 87.8 | IIIB | 60 days (TP) | RT, TACE |
| C007 | 53 | M | alcohol b | Yes | 55.7 | IIIB | 90 days (TP) | RT, RFA, TACE |
| C008 | 58 | M | HCV | Yes | 64 | IVB | no | RT, TACE |
| C009 | 54 | M | HBV | Yes | 55.8 | IVB | 60 days (TP) | RT, TACE |
| C010 | 77 | M | unknown | Yes | 79 | IVB | 28 days (ISE) | RT, TACE |
| C011 | 71 | M | HBV | Yes | 70.6 | IVB | 60 days (TP) | TACE |
| C012 | 74 | M | unknown | No | 58.6 | IIIB | 60 days (TP) | RT, OP, TACE |
| C013 | 59 | M | HCV | Yes | 64.2 | IVB | 14 days (ISE) | TACE |
| C014 | 71 | M | unknown | No | 57.5 | IVB | 60 days (TP) | OP |
| C015 | 77 | M | HCV | Yes | 51.9 | IVB | 21 days (ISE) | OP |
Note: Parentheses indicate the reason for the discontinuation of sorafenib treatment.
a
The tumor stage was determined on enrollment based on the American Joint Committee on Cancer TNM staging system 7th or 8th edition.
b
Consumption for more than 120 g alcohol per day for more than 10 years. F, female; HBV, hepatitis B virus; HCV, hepatitis C virus; ISE, intolerable side effects; LC, liver cirrhosis; M, male; OP, operation; RFA, radiofrequency ablation; RT, radiation therapy; TACE, transcatheter arterial chemoembolization; TP, tumor progression.